Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin

A technology of ulinastatin and lupus erythematosus, which is applied to drugs for the treatment of systemic lupus erythematosus. Ulinastatin, as an application field of drugs for the treatment of systemic lupus erythematosus, can solve problems such as side effects, infection, and unbearable patients

Active Publication Date: 2011-01-26
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The standard treatment of SLE is the use of glucocorticoids and immunosuppressants such as cyclophosphamide, etc., which can be used to relieve symptoms, but they cannot cure SLE. Long-term or high-dose hormone therapy is often accompanied by serious side effects such as infection, gonadal suppression, and Tumors, etc., and cannot significantly affect the progression of the disease or turn into life-threatening renal complications (lupus nephritis)
New immunosuppressants, biological agents, plasma exchange, autologous stem cell transplantation and other treatment methods not only need long-term clinical verification of efficacy, but also the cost of treatment can range from tens of thousands of yuan per year to hundreds of thousands of yuan per year, which is unbearable for many patients , so there is a need to technically develop new methods of treating SLE

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin
  • Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin
  • Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1 Preparation of Ulinastatin dry powder injection

[0013] Take 100 million units of filtered sterilized ulinastatin aqueous solution, add 20 grams of mannitol to dissolve, adjust the pH to neutral, add water for injection to 2000 ml, add sodium chloride to adjust isotonicity, sterile filter, divide into 1000 In a vial, freeze-dried under sterile conditions.

Embodiment 2

[0014] Example 2 Preparation of Ulinastatin Injection

[0015] Take 100 million units of the filtered sterilized ulinastatin aqueous solution, adjust the pH to neutral, add water for injection to 2000 ml, add sodium chloride to adjust isotonicity, sterile filter, and divide into 1000 vials to obtain the final product.

Embodiment 3

[0016] Embodiment 3 The therapeutic effect of ulinastatin on lupus erythematosus mice

[0017] Part 1: Selection and establishment of a lupus-like mouse model of chronic graft-versus-host disease

[0018] The chronic graft-versus-host disease lupus-like (cGVHD) mouse model is a good example of lupus murine nephritis. Several autoantibodies, including anti-dsDNA, ssDNA, and histone antibodies, can appear in the model, and fatal lupus-like nephritis can also occur. Experimental animals 6-8-week-old female (C57BL / 6J×DBA / 2) F1 hybrid mice and 6-8-week-old female DBA / 2 mice, body weight (18-20) g, clean grade. Before and after modeling, blood, urine and basic status were observed, tested and evaluated regularly. Under sterile conditions, the spleen, lymph nodes (mesenteric, inguinal, and neck) and thymus of DBA / 2 mice were removed, minced, ground, washed with PBS, and sieved. The wall of the centrifuge tube was slowly added on top of the mouse lymphocyte separation solution, cen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the use of ulinastatin in the preparation of a medicament for treating systemic lupus erythematosus. The medicament of the invention is derived from natural protein medicaments extracted from human urine, has a stable and reliable quality and fewer unwanted effects and overcomes the shortcomings of generating more side effects, influencing the living quality of a patient,even causing death of the patient and the like when the conventional medicaments such as glucocorticoid, yclophosphamide, azathioprine and cyclosporine A are used for treating the systemic lupus erythematosus. According to the comparative study on the treatment effect of lupous animal models, the treatment effect of the ulinastatin is the same as that of a hormone contrast group.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry. Specifically, the present invention relates to a medicine for the treatment of systemic lupus erythematosus, in particular to the application of ulinastatin as a medicine for the treatment of systemic lupus erythematosus. Background technique [0002] Systemic lupus erythematosus (SLE) is an autoimmune disease that seriously endangers human health. So far, there is no specific and effective treatment at home and abroad. [0003] Systemic lupus erythematosus (SLE) is an autoimmune disease with complex and diverse clinical manifestations, involving multiple systems and organs. Its etiology is still not fully understood, it may be based on genetic factors, stimulated by environmental factors, triggering abnormal immune responses, continuously producing a large number of pathogenic autoantibodies and immune complexes, and immune complexes are widely deposited in tissues. organs, thereby ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/57A61P37/02A61P13/12
Inventor 傅和亮邹春芽吴蓉蓉华明娟陈颖
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com